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The processing of the HIV-1 Pr160gag-pol precursor polyprotein was analyzed in freshly HIV-1-infected MT-4 cultured cells.
Single intermediates of the processing cascade were characterized by immunoblotting using distinct antisera. A potent
inhibitor of the HIV protease (PR), Ro 31-8959, was employed to block cleavage by the mature PR, thus allowing insights
into initial stages of the gag-pol (auto)-catalytical processing. While most known gag-pol cleavages were blocked in the
presence of the inhibitor, the cleavage site between the gag-NC and the pol-p6* domains was still cleaved even in presence
of high amounts (1 mM) of inhibitor, leading to the accumulation of a novel 114-kDa polyprotein comprising p6*-PR-RT-IN.
In the absence of inhibitor no accumulation of p114 was observed. In inhibitor-treated, HIV-1-infected cells a p6*-PR
intermediate was also detected, indicating subsequent cleavage of the PR/RT scissile bond. These results demonstrate
initial cleavage(s) of the gag-pol precursor hydrolyzed by a proteolytic activity different from the mature PR and indicate
that p114 (p6*-PR-RT-IN) and p6*-PR intermediates could play an essential role in the PR activation process. q 1995 Academic
Press, Inc.
Processing of the HIV-1 Pr55gag and Pr160gag-pol (PI). Lysates of freshly infected control- and PI-treated
MT-4 cells (taken 5 days p.i.) were analyzed by immu-polyproteins is an obligatory step in the maturation of
particles to infectious virus and requires the HIV-1 prote- noblotting. In infected noninhibited controls we observed
a 97-kDa and a 107-kDa polypeptide in addition to aase (PR) (1). A prerequisite of the PR-dimer activity is
the conversion of the PR domain from the zymogen-type gp120/160 signal (see below) and few faint bands of
intermediates (Fig. 1) matching the theoretically pre-Pr160gag-pol precursor polyprotein to PR monomers and
subsequent dimerization to enzymatically active prote- dicted processing scheme of gag-pol polypeptides (66
kDa in Table 1). In contrast, in PI-treated cells, the unpro-ase. This process is thought to be initiated by autocata-
lytic cleavages and to be maintained in trans. It is not yet cessed gag-pol precursor and a protein of an apparent
molecular weight of 114 kDa are clearly the predominantclear whether such autoprocessing involves a proteolytic
proteins with molecular weights 66 kDa (Fig. 1, lanemechanism other than that catalyzed by the mature HIV
1). The broad band below the unprocessed gag-pol pre-PR. To investigate the mechanism of zymogen pro-
cursor (p164) (Fig. 1) had been identified before by anti-cessing and to determine nascent proteolytic activities,
gp120 antiserum as gp120/160 (data not shown). Novarious recombinant, truncated gag-pol and pol precur-
p114 is detectable in cells without PI treatment (Fig. 1,sor constructs with mutated cleavage sites to suppress
lane 4).regular processing (PR activation) have been studied (2–
As the next experiment gag-pol processing intermedi-6). The results suggested proteolytically active precursor
ates were further characterized by specific antisera di-forms involving particularly the pol-p6* domain, a se-
rected against gag p24, PR, and RT. As expected, allquence directly upstream of the PR.
antisera show reactivity to the full-length gag-pol precur-We have extended this question to the processing of
sor. In PI-treated cells the processing intermediates p97,the full-length, wild-type Pr160gag-pol polyprotein in freshly
p107, p114, and p121 were detected by anti-RT antise-HIV-infected cultured lymphocytes, thus avoiding recom-
rum; anti-PR antiserum did not recognize p97, confirmingbinant, truncated, or mutated constructs.
that p97 lacks the PR region and comprises only RTGag-pol cleavage intermediates have a short lifetime
(reverse transcriptase) and IN (integrase) domains (Fig.in infected cells. To detect them we tried to delay or
2 and Table 1). Using anti-gag-p24 antiserum, even after‘‘freeze’’ the processing by using a potent PR inhibitor
long-time exposure, only Pr160gag-pol and Pr55gag could
be detected in PI-treated cells (Fig. 2).
In the non-inhibitor-treated control the polypeptide1 To whom reprint requests should be addressed.
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rum (Fig. 4, lane 3) and not by RT antiserum (not shown),
suggesting the presence of a p6*-PR intermediate.
The physiologic course of Pr160gag-pol precursor pro-
cessing and the mechanism of the PR–zymogen conver-
sion into a mature, homodimer enzyme are still not en-
tirely clear. Various experiments (2–5) using truncated
or mutated gag-pol precursors yielded evidence for an
autocatalytic mechanism obviously involving a proteo-
lytic activity intrinsic to the zymogen precursor.
Here, we confirmed these results and extended them
using wild-type virus in a nonrecombinant system and
HIV-permissive cells. To facilitate the dissection of early
intermediates from the bulk of the cleavage steps, the
processing rate was slowed down by employing the po-
tent PR inhibitor Ro 31-8959. Two intermediate polypep-
tides (p114 and p6*-PR) which are not (or only in minuteFIG. 1. Immunoblot analysis of the processing of Pr160gag-pol precur-
amounts) present in untreated HIV-infected controls weresor in the presence or absence of PR inhibitor. MT-4 cells were chosen
because of their high titer of HIV after acute infection (18). MT-4 cells found even in the presence of high (1 mM) concentrations
were infected by HIV-IIIB with a multiplicity of infection (m.o.i.) of 1 for of PR inhibitor. Under these conditions the appearance of
1 hr at 377. As a negative control, an aliquot of 1 1 107 cells was not intermediate p114 is evidentially pronounced, suggesting
infected. One hour after infection cells were sedimented for 2 min at
that the initial cleavage between the gag-NC domain and200 g, the supernatant was removed, and the cells were resuspended
polp6*, insensitive to the PI, occurs autocatalytically asin fresh medium. The cell concentration was adjusted to 1 1 106 MT-
4 cells/ml culture medium and cells were aliquoted. The HIV-1 protease an early step without the help of the mature PR.
inhibitor Ro-31-8959 (19) was added 36 hr p.i. to aliquots of infected Thus, the substrate specificity of the initial cleavage
cells at a final inhibitor concentration of 100 nM. The remaining cells is different from the known one catalyzed by the mature
were mock-treated with 10 or 100 ml DMSO/RPMI and served as in-
PR dimer. We could not determine the exact locus andfected, nontreated positive control. Every day 80% of the medium super-
amino acid sequence of this cleavage site because itnatant was replaced with fresh medium containing the inhibitor, thereby
keeping the final inhibitor concentrations nearly constant. Cells were was unfeasible to collect sufficient purified p114 material
harvested 5 days postinfection, at 114 hr (lanes 1–3) and 120 hr (lanes from the immunoblot for N-terminal microsequencing.
4 and 5). Immunodetection by AIDS patient polyclonal serum: lane 1 Judged from the size of the 114-kDa intermediate prod-
(I), HIV infected and PI treated; lanes 2 and 4 (/), HIV-infected MT-4
uct, the cleavage site is, however, located in a regioncells without inhibitor; lanes 3 and 5 (0), noninfected MT-4 cells. Cell
that the mature PR is not cleaving.lysates were resolved on a 6.5% denaturing polyacrylamide gel.
Two models are conceivable to explain these observa-
tions. First, the initial cleavage of Pr160gag-pol into a gag
and a pol portion might be performed by cellular prote-p107 was detected by anti-PR antiserum, and p97 and
RT66 by anti-RT antiserum. The gag p24 antiserum re- ases, although neither of the amino acid sequences
around the assumed scissile bonds show possible con-peatedly did not react with any polypeptide in the range
of 114 kDa, also excluding the presence of a conceivable sensus sequences for such proteases. Results of other
investigations also argue against this hypothesis as theyp116 intermediate (created by cleavage between RT/IN
and p17/p24) possibly comigrating with p114. All results demonstrated that accurate processing of recombinantly
expressed gag and gag-pol precursors occurred in aare summarized in Table 1.
To enhance the potency of blocking the mature PR variety of heterologous recombinant systems like bacte-
ria, yeast, insect cells, and also during in vitro translation,in another series of experiments we increased the PI
concentration from 100 nM to 1 mM. Here, the intermedi- unlikely to provide the same proteolytic activity (9–12).
A second possibility would be the initial processingate band of p97 (obviously evolved from p114) disap-
peared almost completely, while p114 and Pr160gag-pol by a proteolytic activity associated with or intrinsic to the
Pr160gag-pol precursor. The existence of such a zymogen-clearly showed increased intensity (Fig. 3), supporting
the initial character of the unblocked cleavage event be- like activity has been postulated by others (13) and is also
favored by our results. The appearance of the processingtween NC and p6*.
To detect whether intermediates may accumulate in intermediates p97 (RT–IN) and p107 (PR–RT–IN) (devoid
of the pol-p6* portion) in non-inhibitor-treated, infecteddiscrete cellular compartments (7), lysates were sepa-
rated into cytosol and enriched membrane fractions by cells indicates that the p6*-PR intermediate has a short
half-life and exists only early in the course of processing.ultracentrifugation (8) and analyzed by immunoblots. In
the membrane fraction of PR inhibitor-treated cells, but As soon as sufficient mature PR is produced, trans-pro-
cessing of the scissile bond p6*/PR is achieved followednot in untreated controls, we detected a precursor pro-
tein of about 16 kDa by staining with PR-specific antise- by PR/RT cleavage leading to the products p107, p97,
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TABLE 1
Reactivities of Pr160gag-pol Intermediates to Different Specific Antisera
Note. Cleavage intermediates with molecular weights 66 kDa and their reactivities to different antisera as indicated to the right. MA, matrix
protein; CA, capsid protein; NC, nucleocapsid protein; Fs, frameshift; MW, molecular weight (kDa); HIV, antiserum of AIDS patient. I, HIV-1-infected
MT-4 cells treated with PR inhibitor. *, HIV-1-infected MT-4 cells without PR inhibitor. Molecular weights: PR, 11 kDa; RT, 66 kDa; IN, 31 kDa. //,
strong signal; /, mean signal; (/), weak signal; 0, no signal.
and PR. The appearance of the intermediate p97 further Asn*Phe-Leu sequence (15). Moreover, Jacks and co-
suggests that the cleavage between RT and IN is a rather workers (16) evaluated from in vitro experiments that the
late event during the Pr160gag-pol processing. same cleavage site (Ala-Asn*Phe-Leu) emerges at a rate
A potential candidate for an initial cleavage event be- of 70% at the frameshift site.
tween NC and p6*, releasing a p114 intermediate, is the A further potential cleavage site for the discon-
cleavage site Ala-Asn*Phe-Leu. Interestingly, the mature nection of the gag and pol reading frames is the se-
PR does not cleave this cleavage site (14) and yet pro- quence Ala-Phe*Leu-Gln (4). This sequence located
teins NC and p1 are found in virus particles which could
have only been generated by processing of this Ala-
FIG. 2. Immunoblot analysis of Pr160gag-pol precursor processing es-
sentially as in Fig. 1 but employing different antisera. Immunostaining
of the blotted proteins was performed with anti-RT (Neosystems, Stras- FIG. 3. Pr160gag-pol processing pattern at different inhibitor concentra-
tions. Cell lysates were analyzed by immunoblotting with monoclonalbourg, France), anti-PR (kind gift of M. Graves, Roche Nutley, USA),
and anti-gag p24 (Biochrom, Berlin, Germany). 0, noninfected control; anti-RT antibody. /, infected cells without PR inhibitor. I, HIV-infected
and PI-treated cells (100 nM or 1 mM). Cell lysates were resolved on/, HIV infected; I, HIV infected and PI treated. Cell lysates were re-
solved on a 7.5% denaturing polyacrylamide gel. a 7.5% denaturing polyacrylamide gel.
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An activity with a substrate specificity different from
the mature PR is a valuable additional target for a novel
type of PR inhibitors specifically blocking the initial au-
tocleavage of the PR.
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